A study of the prevalence of H. pylori in MCSC
NewsSpecialists of MCSC named after A.S. Loginov conduct an epidemiological study of the prevalence of H. pylori and precancerous changes in Moscow patients.
- The bacterium H. pylori is transmitted from person to person, most often in childhood, and causes chronic active gastritis in all infected.
- Long-term inflammation, having passed the stages of atrophic gastritis of varying severity (precancerous changes), in some cases leads to the development of adenocarcinoma (cancer) of the stomach. The risk is especially high in first-line relatives of patients with stomach cancer.
About 36 thousand new cases of stomach cancer are registered annually in Russia, more than 34 thousand patients die from this disease.
- In Moscow, stomach cancer is on the 5th place in the structure of malignant neoplasms.
At the first stage, stomach cancer is detected only in 21% of cases. Late diagnosis is the cause of poor prognosis: within the first year after diagnosis, about 40% of patients die.
Stomach cancer can be prevented, since at least 90% of cases of this disease are caused by the bacterium H. pylori. The prevalence of H. pylori in Moscow is estimated at 50%. In most cases, it is asymptomatic.
- Timely detection and treatment of helicobacter infection can dramatically reduce the risk of developing stomach cancer (primary prevention), as well as peptic ulcer of the stomach and duodenum.
- Assessment of the condition of the gastric mucosa according to endoscopic and morphological examination using the OLGA system allows determining the individual risk of developing gastric cancer and developing a program for its prevention (secondary prevention).
- The Gastropanel blood test helps to determine the indications for endoscopy, highlighting people with a high risk of atrophy.
The best results can be obtained by a combination of primary prevention (detection and treatment of H. pylori) and secondary (timely detection of precancerous changes in the gastric mucosa).
All those invited to take part in the study will be given free:
- 13 C-urease breath test for H. pylori;
- "Gastropanel" is a blood test to determine the level of serological markers of gastric mucosal atrophy (pepsinogen I and II, gastrin-17), as well as antibodies to H. pylori.
Within a month before the test, it is necessary to stop taking any antibiotics, bismuth-containing drugs (de-nol, ulkavis), 2 weeks before the test, proton pump inhibitors (omeprazole, pantoprazole, rabeprazole, esomeprazole, dexlansoprazole) should be excluded.
In case of identification of atrophy markers, the study participants will be asked to undergo a gastroscopy followed by a morphological examination using the OLGA system.
